Recent VIGL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/19/2024 09:20:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/17/2024 11:16:00 AM
- Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- Vigil Neuroscience to Present at Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/16/2024 08:05:00 PM
- Vigil Neuroscience to Present at Upcoming September Investor Conferences • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:16:04 AM
- Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/12/2024 09:02:26 PM
- Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC) • GlobeNewswire Inc. • 07/30/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:15:52 AM
- Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease • GlobeNewswire Inc. • 07/24/2024 11:00:00 AM
- Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference • GlobeNewswire Inc. • 07/18/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 11:15:31 AM
- Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP • GlobeNewswire Inc. • 07/18/2024 11:00:00 AM
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi • GlobeNewswire Inc. • 06/27/2024 06:00:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:55 PM
- Vigil Neuroscience to Present in Upcoming June Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:05:00 AM
- Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/08/2024 11:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 09:00:27 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM